# A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

> **NCT04179045** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Bio-heart Biological Technology Co., Ltd.** · enrollment: 785 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

## Key facts

- **NCT ID:** NCT04179045
- **Lead sponsor:** Shanghai Bio-heart Biological Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2022-07
- **Final completion:** 2026-07
- **Target enrollment:** 785 (ESTIMATED)
- **Last updated:** 2021-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179045, "A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04179045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*